Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

ClinicalTrials.gov ID: NCT02598661

Public ClinicalTrials.gov record NCT02598661. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Study identification

NCT ID
NCT02598661
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Geron Corporation
Industry
Enrollment
289 participants

Conditions and interventions

Interventions

  • Imetelstat Sodium Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 11, 2016
Primary completion
Oct 12, 2023
Completion
Oct 12, 2026
Last update posted
Jan 4, 2026

2016 – 2026

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
19
Facility City State ZIP Site status
UAB Comprehensive Cancer Center Birmingham Alabama 35294
Acrc/Arizona Clinical Research, Inc. Tucson Arizona 85715
CBCC Global Research, Inc. Bakersfield California 93309
UCLA Ronald Regan Medical Center Los Angeles California 90095
Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital New Haven Connecticut 06510-3220
BRCR Medical Center Plantation Florida 33326
University of South Florida (USF) - H. Lee Moffitt Cancer Center Tampa Florida 33612
Franciscan Health Indianapolis Indiana 46237-8601
St. Agnes Healthcare, Inc Baltimore Maryland 21229
Center for Cancer and Blood Disorders Bethesda Maryland 20817
Washington University School of Medicine St Louis Missouri 63110
University of New Mexico Cancer Center Albuquerque New Mexico 87131
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects New York New York 10029
Columbia University Medical Center New York New York 10032
Weill Cornell Medical College-New York Presbyterian Hospital New York New York 10065
Cleveland Clinic Taussig Cancer Cleveland Ohio 44195
The Ohio State Comprehensive Cancer Center Columbus Ohio 43210
Prairie lakes Healthcare system, Inc Watertown South Dakota 57201
Vanderbilt University Medical - Hematology-Oncology Nashville Tennessee 37232-6307
Texas Oncology/Methodist Charlton Cancer Center Dallas Texas 75237
Simmons Comprehensive Cancer Center Dallas Texas 75390
Fred Hutchinson Cancer Research Center (FHCRC) Seattle Washington 98109-1024

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02598661, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2026 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02598661 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →